Xin-Li formula attenuates heart failure induced by a combination of hyperlipidemia and myocardial infarction in rats via Treg immunomodulation and NLRP3 inflammasome inhibition

10.1016/j.jtcme.2023.03.009

Taohua Lan；Qiaohuang Zeng；Ying Zhu；Guangjuan Zheng；Keji Chen；Wei Jiang；Weihui Lu

Xin-Li Formula ； Heart failure ； Regulatory T cell ； Immune regulation ； Anti-inflammation

Journal of Traditional and Complementary Medicine

13卷5期（2023 / 09 / 01）

441 - 453

英文

Background and aim: Heart failure (HF) is a complex clinical syndrome that represents the end result of several pathophysiologic processes. Despite a dramatic evolution in diagnosis and management of HF, most patients eventually become resistant to therapy. Xin-Li Formula (XLF) is a Chinese medicine formula which shows great potential in the treatment of HF according to our previous studies. The present study was designed to investigate the effects of XLF on HF induced by a combination of hyperlipidemia and myocardial infarction (MI) in rats and reveal the underlying mechanism. Experimental procedure: A rat model of HF induced by hyperlipidemia and MI was established with intragastric administration of XLF and Perindopril. In vitro, CD4^+ T cells from mouse spleen and LPS/ATP-stimulated THP-1 macrophages were employed. Results and conclusion: XLF was shown to have markedly protective effects on MI-induced HF with hyperlipidemia in rats, including improvement of left ventricular function, reduction of left ventricular fibrosis and infarct size. Moreover, XLF administration significantly increased the number of Foxp3^+ Tregs, and inhibited mTOR phosphorylation and NLRP3 signaling pathway. In vitro, we found that XLF had induced Treg activation via the inhibition of mTOR phosphorylation in CD4^+ T cells. Additionally, XLF inhibited NLRP3 inflammasome activation in LPS/ATP-stimulated THP-1 macrophages. Taken together, this study raises the exciting possibility that Xin-Li Formula may benefit HF patients due to its immunomodulatory and anti-inflammatory effects via Treg activation and NLRP3 inflammasome inhibition.

1. Adamo, L,Rocha-Resende, C,Prabhu, SD,Mann, DL(2020).Reappraising the role of inflammation in heart failure.Nat Rev Cardiol,17(5),269-285.
2. Bansal, SS,Ismahil, MA,Goel, M(2017).Activated T lymphocytes are essential drivers of pathological remodeling in ischemic heart failure.Circ Heart Fail,10(3),e3688.
3. Bansal, SS,Ismahil, MA,Goel, M(2019).Dysfunctional and proinflammatory regulatory T-lymphocytes are essential for adverse cardiac remodeling in ischemic cardiomyopathy.Circulation,139(2),206-221.
4. Battaglia, M,Stabilini, A,Migliavacca, B,Horejs-Hoeck, J,Kaupper, T,Roncarolo, MG(2006).Rapamycin promotes expansion of functional CD4þCD25þFOXP3þ regulatory T cells of both healthy subjects and type 1 diabetic patients.J Immunol,177(12),8338-8347.
5. Bergstrom, M,Muller, M,Karlsson, M,Scholz, H,Vethe, NT,Korsgren, O(2019).Comparing the effects of the mTOR inhibitors azithromycin and rapamycin on in vitro expanded regulatory T cells.Cell Transplant,28(12),1603-1613.
6. Brown, EJ,Albers, MW,Shin, TB(1994).A mammalian protein targeted by G1-arresting rapamycin-receptor complex.Nature,369(6483),756-758.
7. Chapman, NM,Chi, H(2014).mTOR signaling, Tregs and immune modulation.Immunotherapy-Uk,6(12),1295-1311.
8. Chen, Y,Colello, J,Jarjour, W,Zheng, SG(2019).Cellular metabolic regulation in the differentiation and function of regulatory T cells.Cells-Basel,8(2),188.
9. Del, BM,Crea, F,Versaci, F,Biondi-Zoccai, G(2021).NLRP3 inflammasome: a new promising therapeutic target to treat heart failure.J Cardiovasc Pharmacol,77(2),159-161.
10. Dong, T,Wang, J,Ma, X(2018).Shexiang Baoxin Pills as an adjuvant treatment for chronic heart failure: a system review and meta-analysis.Evid Based Complement Alternat Med,2018,6949348.
11. Dorneles, GP,Dos, PA,Romao, P,Peres, A(2020).New insights about regulatory T cells distribution and function with exercise: the role of immunometabolism.Curr Pharmaceut Des,26(9),979-990.
12. Du, Y,Gu, X,Meng, H(2018).Muscone improves cardiac function in mice after myocardial infarction by alleviating cardiac macrophage-mediated chronic inflammation through inhibition of NF-kappaB and NLRP3 inflammasome.Am J Transl Res,10(12),4235-4246.
13. Everett, BM,Cornel, JH,Lainscak, M(2019).Anti-inflammatory therapy with canakinumab for the prevention of hospitalization for heart failure.Circulation,139(10),1289-1299.
14. Fan, W,Zhang, B,Wu, C(2021).Plantago asiatica L. seeds extract protects against cardiomyocyte injury in isoproterenol- induced cardiac hypertrophy by inhibiting excessive autophagy and apoptosis in mice.Phytomedicine,91,153681.
15. Fan, Y,Zhang, K(2021).Verbascoside inhibits the progression of atherosclerosis in high fat diet induced atherosclerosis rat model.J Physiol Pharmacol,72(3)
16. Ferreira, L,Muller, YD,Bluestone, JA,Tang, Q(2019).Next-generation regulatory T cell therapy.Nat Rev Drug Discov,18(10),749-769.
17. Hao, G,Wang, X,Chen, Z(2019).Prevalence of heart failure and left ventricular dysfunction in China: the China Hypertension Survey, 2012-2015.Eur J Heart Fail,21(11),1329-1337.
18. Hendrikx, TK,Velthuis, JH,Klepper, M(2009).Monotherapy rapamycin allows an increase of CD4 CD25 FoxP3 T cells in renal recipients.Transpl Int,22(9),884-891.
19. Hofmann, U,Beyersdorf, N,Weirather, J(2012).Activation of CD4þ T lymphocytes improves wound healing and survival after experimental myocardial infarction in mice.Circulation,125(13),1652-1663.
20. Huang, H,Long, L,Zhou, P,Chapman, NM,Chi, H(2020).mTOR signaling at the crossroads of environmental signals and T-cell fate decisions.Immunol Rev,295(1),15-38.
21. Karmazyn, M,Gan, XT(2017).Treatment of the cardiac hypertrophic response and heart failure with ginseng, ginsenosides, and ginseng-related products.Can J Physiol Pharmacol,95(10),1170-1176.
22. Kim, J,Guan, KL(2019).mTOR as a central hub of nutrient signalling and cell growth.Nat Cell Biol,21(1),63-71.
23. Latz, E,Xiao, TS,Stutz, A(2013).Activation and regulation of the inflammasomes.Nat Rev Immunol,13(6),397-411.
24. Li, R,Lu, K,Wang, Y(2017).Triptolide attenuates pressure overload-induced myocardial remodeling in mice via the inhibition of NLRP3 inflammasome expression.Biochem Biophys Res Commun,485(1),69-75.
25. Li, X,Zhang, J,Huang, J(2013).A multicenter, randomized, double-blind, parallelgroup, placebo-controlled study of the effects of qili qiangxin capsules in patients with chronic heart failure.J Am Coll Cardiol,62(12),1065-1072.
26. Manolis, AS,Manolis, AA,Manolis, TA,Melita, H(2019).Sudden death in heart failure with preserved ejection fraction and beyond: an elusive target.Heart Fail Rev,24(6),847-866.
27. Meng, X,Yang, J,Dong, M(2016).Regulatory T cells in cardiovascular diseases.Nat Rev Cardiol,13(3),167-179.
28. Murphy, SP,Kakkar, R,McCarthy, CP,Januzzi, JJ(2020).Inflammation in heart failure: JACC state-of-the-art review.J Am Coll Cardiol,75(11),1324-1340.
29. Pellegrini, C,Martelli, A,Antonioli, L,Fornai, M,Blandizzi, C,Calderone, V(2021).NLRP3 inflammasome in cardiovascular diseases: pathophysiological and pharmacological implications.Med Res Rev,41(4),1890-1926.
30. Saxton, RA,Sabatini, DM(2017).mTOR signaling in growth, metabolism, and disease.Cell,168(6),960-976.
31. Sharir, R,Semo, J,Shimoni, S(2014).Experimental myocardial infarction induces altered regulatory T cell hemostasis, and adoptive transfer attenuates subsequent remodeling.PLoS One,9(12),e113653.
32. Sun, X,Lan, J,Tong, R(2019).An integrative investigation on the efficacy of Plantaginis semen based on UPLC-QTOF-MS metabolomics approach in hyperlipidemic mice.Biomed Pharmacother,115,108907.
33. Swanson, KV,Deng, M,Ting, JP(2019).The NLRP3 inflammasome: molecular activation and regulation to therapeutics.Nat Rev Immunol,19(8),477-489.
34. Tang, TT,Yuan, J,Zhu, ZF(2012).Regulatory T cells ameliorate cardiac remodeling after myocardial infarction.Basic Res Cardiol,107(1),232.
35. Tang, TT,Zhu, ZF,Wang, J(2011).Impaired thymic export and apoptosis contribute to regulatory T-cell defects in patients with chronic heart failure.PLoS One,6(9),e24272.
36. Trankle, CR,Canada, JM,Cei, L(2018).Usefulness of canakinumab to improve exercise capacity in patients with long-term systolic heart failure and elevated C-reactive protein.Am J Cardiol,122(8),1366-1370.
37. Wang, Y,Liu, X,Shi, H(2020).NLRP3 inflammasome, an immune-inflammatory target in pathogenesis and treatment of cardiovascular diseases.Clin Transl Med,10(1),91-106.
38. Weirather, J,Hofmann, UD,Beyersdorf, N(2014).Foxp3þ CD4þ T cells improve healing after myocardial infarction by modulating monocyte/macrophage differentiation.Circ Res,115(1),55-67.
39. Wigren, M,Bjorkbacka, H,Andersson, L(2012).Low levels of circulating CD4þFoxP3þ T cells are associated with an increased risk for development of myocardial infarction but not for stroke.Arterioscler Thromb Vasc Biol,32(8),2000-2004.
40. Wu, H,Zhao, G,Jiang, K(2016).Plantamajoside ameliorates lipopolysaccharideinduced acute lung injury via suppressing NF-kappaB and MAPK activation.Int Immunopharm,35,315-322.
41. Xiao, J,Yu, K,Li, M,Xiong, C,Wei, Y,Zeng, Q(2017).The IL-2/anti-IL-2 complex attenuates cardiac ischaemia-reperfusion injury through expansion of regulatory T cells.Cell Physiol Biochem,44(5),1810-1827.
42. Yancy, CW,Jessup, M,Bozkurt, B(2013).ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.Circulation,128(16),e240-e327.
43. Yang, QY,Chen, KJ,Lu, S,Sun, HR(2012).Research progress on mechanism of action of Radix Astragalus in the treatment of heart failure.Chin J Integr Med,18(3),235-240.
44. Zang, Y,Wan, J,Zhang, Z,Huang, S,Liu, X,Zhang, W(2020).An updated role of astragaloside IV in heart failure.Biomed Pharmacother,126,110012.
45. Zeng, Z,Yu, K,Chen, L,Li, W,Xiao, H,Huang, Z(2016).Interleukin-2/Anti-Interleukin-2 immune complex attenuates cardiac remodeling after myocardial infarction through expansion of regulatory T cells.J Immunol Res,2016,8493767.
46. Zhao, M,Hao, M,Tong, H(2022).Screening of blood-activating active components from Curcuma wenyujin Y.H. Chen et C. Ling rhizome based on spectrum-effect relationship analysis and network pharmacology.J Chromatogr, B: Anal Technol Biomed Life Sci,1188,123022.
47. Zheng, Y,Collins, SL,Lutz, MA(2007).A role for mammalian target of rapamycin in regulating T cell activation versus anergy.J Immunol,178(4),2163-2170.
48. Zhuang, R,Feinberg, MW(2020).Regulatory T cells in ischemic cardiovascular injury and repair.J Mol Cell Cardiol,147,1-11.